A Multicenter, Prospective, Open-label, Randomized Controlled Study to Evaluate the Safety of Short-term Dual Antiplatelet Therapy after Coronary Stenting with the Everolimus-Eluting Stent in Patients with Coronary artery disease
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0008411
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 2018
? Adults 19 years of age or older
? Patients with coronary artery disease requiring coronary intervention
? Patients who underwent percutaneous coronary intervention with centum stent, everolimus-eluting stent
? Subjects with known history of severe hypersensitivity reactions to aspirin, clopidogrel, everolimus, contrast agent
? If there is clinically active bleeding at the time of study enrollment (active bleeding)
? Subjects who underwent stenting in the unprotected left main coronary artery
? Subjects whose life expectancy is less than 1 year for reasons other than cardiovascular disease
? Pregnant or lactating women
? If it is difficult to maintain dual antiplatelet therapy for anticoagulant treatment due to atrial fibrillation, etc.
? Inability to provide informed consent
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse cardiac and cerebrovascular events: all cause death, target-vessel myocardial infarction, target lesion revascularization, and stent thrombosis, stroke
- Secondary Outcome Measures
Name Time Method All-cause and cardiac death, MI (target vessel or any), Any repeat revascularization, Clinically-indicated target lesion revascularization (TLR), Clinically-indicated target vessel revascularization (TVR), Patient-oriented composite endpoint, Device-oriented composite endpoint, Stent thrombosis (ARC definition), Stroke,TIMI major and minor bleeding, BARC bleeding (3/5 and 2/3/5)